Pathology |
Biomarker |
Level |
Source |
Study type |
Potential |
Ref. |
Prostate Cancer (PC) |
miR-375 and miR-141 |
Up-regulation |
Serum |
Cohort Study |
Diagnosis and Stage Determination |
54
54 Bryant R, Pawlowski T, Catto J, Marsden G, Vessella R, Rhees B, et al. Changes in circulating microRNA levels associated with prostate cancer. British journal of cancer. 2012;106(4):768-74.
|
miR-107 and miR-574-3p |
Up-regulation |
Urine |
miR-34a |
Down-regulation |
Cell line conditioned medium (CM) |
Cell Line Models |
Predictive Biomarker for Response to Docetaxel in PCa Progression |
69
69 Corcoran C, Rani S, O'Driscoll L. miR-34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression. The Prostate. 2014;74(13):1320-34.
|
miR-1290 and miR-375 |
Higher |
Plasma |
Cohort Study |
Prognostic Biomarker in Castration-Resistant PCa |
70
70 Huang X, Yuan T, Liang M, Du M, Xia S, Dittmar R, et al. Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer. European urology. 2015;67(1):33-41.
|
hsa-41 miR375, hsa-miR21 and hsa-miR574 |
Higher |
Serum |
Non Cohort Study |
Discriminating Biomarker |
71
71 Li M, Rai AJ, DeCastro GJ, Zeringer E, Barta T, Magdaleno S, et al. An optimized procedure for exosome isolation and analysis using serum samples: Application to cancer biomarker discovery. Methods. 2015;87:26-30.
|
miR-141 |
Up-regulation |
Serum |
Cohort Study |
Diagnosis |
72
72 Li Z, Ma Y-Y, Wang J, Zeng X-F, Li R, Kang W, et al. Exosomal microRNA-141 is upregulated in the serum of prostate cancer patients. OncoTargets and therapy. 2016;9:139.
|
miR-574-3p, miR-141-5p and miR-21-5p |
Up-regulation |
Urine |
Non Cohort Study and Cell Line Model |
Diagnosis |
73
73 Samsonov R, Shtam T, Burdakov V, Glotov A, Tsyrlina E, Berstein L, et al. Lectin-induced agglutination method of urinary exosomes isolation followed by mi-RNA analysis: Application for prostate cancer diagnostic. The Prostate. 2016;76(1):68-79.
|
Ovarian Cancer |
miR-21, miR-214, miR-200a, miR-200b, miR-200c, miR-203, miR-205 and miR-141 |
Elevated |
Serum |
Non Cohort Study |
Diagnosis |
52
52 Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecologic oncology. 2008;110(1):13-21.
|
Let-7 |
High expression in SKOV-3 |
Cell Culture Media |
Cell Line Models (SKOV-3 and OVCAR-3) |
Diagnosis |
74
74 Kobayashi M, Salomon C, Tapia J, Illanes SE, Mitchell MD, Rice GE. Ovarian cancer cell invasiveness is associated with discordant exosomal sequestration of Let-7 miRNA and miR-200. Journal of translational medicine. 2014;12:4. PubMed PMID: 24393345. Pubmed Central PMCID: 3896684. Epub 2014/01/08. eng.
|
miR-200 |
Expressed only in OVCAR-3 |
miR-21 |
Over Expression |
- |
Non Study Cohort |
Diagnosis |
75
75 Cappellesso R, Tinazzi A, Giurici T, Simonato F, Guzzardo V, Ventura L, et al. Programmed cell death 4 and microRNA 21 inverse expression is maintained in cells and exosomes from ovarian serous carcinoma effusions. Cancer cytopathology. 2014;122(9):685-93.
|
miR-30a-5p |
Up-regulation |
Urine |
Non Study Cohort and Cell Line Model |
Diagnostic and Therapeutic target of Ovarian Serous Carcinoma |
76
76 Zhou J, Gong G, Tan H, Dai F, Zhu X, Chen Y, et al. Urinary microRNA-30a-5p is a potential biomarker for ovarian serous adenocarcinoma. Oncology reports. 2015;33(6):2915-23.
|
miR-373, miR-200a, miR-200b and miR- 200c |
Elevated |
Serum |
Cohort Study |
Diagnosis and Prognosis |
55
55 Meng X, Muller V, Milde-Langosch K, Trillsch F, Pantel K, Schwarzenbach H. Diagnostic and prognostic relevance of circulating exosomal miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer. Oncotarget. 2016.
|
Breast Cancer |
miR-21 and miR-146ª |
Over expression |
Plasma |
Non Cohort Study |
Diagnosis |
62
62 Ogata-Kawata H, Izumiya M, Kurioka D, Honma Y, Yamada Y, Furuta K, et al. Circulating exosomal microRNAs as biomarkers of colon cancer. PloS one. 2014;9(4):e92921.
|
miR-106a |
Up-regulated |
Plasma |
Non Cohort Study |
Biomarker for metastatic Breast Cancer |
77
77 Zhao Q, Deng S, Wang G, Liu C, Meng L, Qiao S, et al. A direct quantification method for measuring plasma MicroRNAs identified potential biomarkers for detecting metastatic breast cancer. Oncotarget. 2016.
|
Colorectal Cancer (CRC) |
let-7a, miR-1246, miR-1229, miR-23a, miR-223, miR-21, and miR-150 |
Higher |
Serum |
Non Cohort Study |
Diagnosis |
62
62 Ogata-Kawata H, Izumiya M, Kurioka D, Honma Y, Yamada Y, Furuta K, et al. Circulating exosomal microRNAs as biomarkers of colon cancer. PloS one. 2014;9(4):e92921.
|
miR-19a |
Over expression |
Serum |
Non Cohort Study |
Prognostic Biomarker |
78
78 Matsumura T, Sugimachi K, Iinuma H, Takahashi Y, Kurashige J, Sawada G, et al. Exosomal microRNA in serum is a novel biomarker of recurrence in human colorectal cancer. British journal of cancer. 2015;113(2):275-81.
|
miR-372 |
Up-regulation |
Serum |
Non Cohort Study |
Diagnosis and Prognosis |
56
56 Yu J, Jin L, Li W, Jiang L, Hu Y, Zhi Q, et al. Serum miR-372 is a diagnostic and prognostic biomarker in patients with early colorectal cancer. Anti-cancer agents in medicinal chemistry. 2015.
|
Lung Cancer |
miR-125a-5p, miR-145 and miR-146a* |
Over expression |
Serum |
Non Cohort Study |
Diagnosis |
79
79 Wang R-J, Zheng Y-H, Wang P, Zhang J-Z. Serum miR-125a-5p, miR-145 and miR-146a as diagnostic biomarkers in non-small cell lung cancer. International journal of clinical and experimental pathology. 2015;8(1):765.
|
miR-29a-3p and miR-150-5p |
Down-regulation |
Plasma |
Cohort Study |
Predict response To Radiation Therapy |
80
80 Dinh T-KT, Fendler W, Chalubinska-Fendler J, Acharya SS, O'Leary C, Deraska PV, et al. Circulating miR-29a and miR-150 correlate with delivered dose during thoracic radiation therapy for non-small cell lung cancer. Radiation Oncology. 2016;11(1):1.
|
miR-21 and miR-155 |
Up-regulation |
Serum and Conditioned media |
Non Study Cohort (Cell lines and recurrent nude mouse xenograft) |
Diagnosis |
81
81 Munagala R, Aqil F, Gupta RC. Exosomal miRNAs as biomarkers of recurrent lung cancer. Tumor Biology. 2016:1-12.
|
Gastric Cancer (GC) |
miR-214, miR-221 and miR-222 |
Up-regulation |
Serum |
Non Cohort Study |
Diagnosis and Prognosis |
82
82 Wang M, Zhao C, Shi H, Zhang B, Zhang L, Zhang X, et al. Deregulated microRNAs in gastric cancer tissue-derived mesenchymal stem cells: novel biomarkers and a mechanism for gastric cancer. British journal of cancer. 2014;110(5):1199-210.
|
miR-21 and miR-1225-5p |
Higher |
Malignant ascites and Peritoneal lavage fluid |
Non Cohort Study |
Diagnosis and Prognosis of Peritoneum Dissection of Gastric Cancer |
60
60 Tokuhisa M, Ichikawa Y, Kosaka N, Ochiya T, Yashiro M, Hirakawa K, et al. Exosomal miRNAs from peritoneum lavage fluid as potential prognostic biomarkers of peritoneal metastasis in gastric cancer. PloS one. 2015;10(7):e0130472.
|
Cervical Cancer (CC) |
miR-21 and miR-146a |
Up-regulation |
Cervicovaginal lavage Fluid |
Non Cohort Study |
Non-invasive CC screening |
58
58 Liu J, Sun H, Wang X, Yu Q, Li S, Yu X, et al. Increased exosomal microRNA-21 and microRNA-146a levels in the cervicovaginal lavage specimens of patients with cervical cancer. International journal of molecular sciences. 2014;15(1):758-73.
|
Retinoblastoma |
miR-320, miR-let-7e, and miR-21 |
Down-regulation |
Plasma |
Non Cohort Study |
Diagnosis |
59
59 Liu SS, Wang YS, Sun YF, Miao LX, Wang J, Li YS, et al. Plasma microRNA-320, microRNA-let-7e and microRNA-21 as novel potential biomarkers for the detection of retinoblastoma. Biomedical reports. 2014;2(3):424-8.
|
|
|
|
|
|
|
|
Osophageal squamous cell carcinoma (ESCC) |
miR-1246 |
Up-regulation |
Serum |
Non Cohort Study |
Diagnosis and Prognosis |
83
83 Takeshita N, Hoshino I, Mori M, Akutsu Y, Hanari N, Yoneyama Y, et al. Serum microRNA expression profile: miR-1246 as a novel diagnostic and prognostic biomarker for oesophageal squamous cell carcinoma. British journal of cancer. 2013;108(3):644-52.
|
Hepatocellular Carcinoma (HCC) |
miR-18a, miR-221, miR-222, and miR-224 |
Up-regulation |
Serum |
Non Cohort Study |
Diagnosis |
84
84 Sohn W, Kim J, Kang SH, Yang SR, Cho J-Y, Cho HC, et al. Serum exosomal microRNAs as novel biomarkers for hepatocellular carcinoma. Experimental & molecular medicine. 2015;47(9):e184.
|
miR-101, miR-106b, miR-122, and miR-195 |
Down- Regulation |
Pancreatic Cancer |
miR-17-5p and miR-21 |
Higher |
Serum |
Non Cohort Study |
Diagnosis |
61
61 Que R, Ding G, Chen J, Cao L. Analysis of serum exosomal microRNAs and clinicopathologic features of patients with pancreatic adenocarcinoma. World journal of surgical oncology. 2013;11(1):1.
|
Laryngeal Squamous Cell Carcinoma |
miR-21and HOTAIR (lncRNA) |
Higher |
Serum |
Non Cohort Study |
Diagnosis and Prognosis |
63
63 Wang J, Zhou Y, Lu J, Sun Y, Xiao H, Liu M, et al. Combined detection of serum exosomal miR-21 and HOTAIR as diagnostic and prognostic biomarkers for laryngeal squamous cell carcinoma. Medical Oncology. 2014;31(9):1-8.
|
Papillary Thyroid Cancer (PTC) |
miR-146b and miR-222 |
Over expression |
- |
Cell Line Model |
Biomarker of PTC recurrence |
85
85 Lee JC, Zhao J-T, Gundara J, Serpell J, Bach LA, Sidhu S. Papillary thyroid cancer-derived exosomes contain miRNA-146b and miRNA-222. Journal of Surgical Research. 2015;196(1):39-48.
|
Melanoma |
miR-125b |
Down-regulation |
Serum |
Non Cohort Study |
Prognosis |
86
86 Alegre E, Sanmamed MF, Rodriguez C, Carranza O, Martin-Algarra S, Gonzalez A. Study of circulating microRNA-125b levels in serum exosomes in advanced melanoma. Archives of Pathology and Laboratory Medicine. 2014;138(6):828-32.
|
Glioblastoma |
miR-320 and miR-574-3p |
- |
Serum |
Cohort Study |
Diagnosis |
42
42 Manterola L, Guruceaga E, Pérez-Larraya JG, González-Huarriz M, Jauregui P, Tejada S, et al. A small noncoding RNA signature found in exosomes of GBM patient serum as a diagnostic tool. Neuro-oncology.2014:not218.
|
RNU6-1 (snRNA) |
Up-regulation |